Jason Valent is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 249 publications with 2,667 citations (h-index 25); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
16761 Southpark Ctr
St30
Strongsville, OH 441369302
Telephone
440-878-2500Registry record last updated 14 Oct 2011.
Clinical trials
- Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Sponsor: Case Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- Legend Biotech USA Inc.Program year20241 payment
- ABBVIE INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.9%Thalidomide Analog24.4%Lenalidomide37%Revlimid34%Pomalyst29%Part D≥30 patientsProteasome Inhibitor3.7%Ninlaro100%Part D≥14 patients+ 2 more classes in this area
Nervous system
22.1%Opioid Agonist6.1%Oxycodone-Acetaminophen35%Hydromorphone Hcl25%Morphine Sulfate Er16%Oxycodone Hcl16%Fentanyl8%Part D<11 patientsGabapentinoids5.6%Gabapentin77%Pregabalin23%Part D<11 patients+ 7 more classes in this area
Dermatology
15.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.1%Acyclovir100%Part D≥80 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024 - Current Novel Targeted Therapeutic Strategies in Multiple Myeloma
International Journal of Molecular Sciences
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Lars Svensson, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Gene Barnett, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”